| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1378040 | Bioorganic & Medicinal Chemistry Letters | 2007 | 4 Pages |
New 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives were prepared and tested for cytotoxic activity on five cancer cell lines in vitro: all tested compounds showed stronger cytotoxic activity than 23-hydroxy betulinic acid and betulinic acid. In addition, compound 5a was tested for anti-tumor activity in vivo: it had much better anti-tumor activity than 23-OH betulinic acid and had similar anti-tumor activity with cyclophosphamide and 5-fluorouracil.
Graphical abstractThe derivatives 5a–f of 23-hydroxy betulinic acid have better cytotoxicity than 23-hydroxy betulinic acid and betulinic acid in vitro. And they are also more potent than 23-hydroxy betulinic acid in vivo. The research results have been applied China Patent: CN 10040277.2, 2006.Figure optionsDownload full-size imageDownload as PowerPoint slide
